ProKidney reports wider quarterly loss and lower revenue
ProKidney posted Q2 2026 revenue of $150,000, down 32.13% from a year earlier.
Net loss before noncontrolling interest widened to $46.4 million from $37 million a year earlier.
R&D expense climbed 39.39% to $36.1 million, driven by higher clinical study and related manufacturing costs tied to PROACT 1.
Cash, cash equivalents and marketable securities fell to $181.6 million at June 30 from $224.9 million at March 31, supporting operations into mid-2027.
The company completed enrollment for the PROACT 1 accelerated approval analysis, with pivotal eGFR slope topline results anticipated in Q2 2027.
PROK•
